Low prevalence of liver disease but regional differences in HBV treatment characteristics mark HIV/HBV co-infection in a South African HIV clinical trial

PLoS ONE

Volumn 8, Issue 12, 2013, Pages

  Ive, Prudence ^a   MacLeod, William ^a,b   Mkumla, Nompumelelo ^a   Orrell, Catherine ^c   Jentsch, Ute ^d   Wallis, Carole L ^a   Stevens, Wendy ^a   Wood, Robin ^c   Sanne, Ian ^a   Bhattacharya, Debika ^e  

^a UNIVERSITY OF THE WITWATERSRAND   (South Africa)

^b BOSTON UNIVERSITY SCHOOL OF PUBLIC HEALTH   (United States)

^c UNIVERSITY OF CAPE TOWN   (South Africa)

^d UNIVERSITY OF THE WITWATERSRAND   (South Africa)

^e UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ANTIRETROVIRUS AGENT; ASPARTATE AMINOTRANSFERASE; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B(E) ANTIGEN; VIRUS DNA;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANTIVIRAL THERAPY; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CD4 LYMPHOCYTE COUNT; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE COURSE; DISEASE SEVERITY; FEMALE; FIB 4 SCORE; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIVER FIBROSIS; MAJOR CLINICAL STUDY; MALE; NUCLEOTIDE SEQUENCE; PREVALENCE; PROSPECTIVE STUDY; SCORING SYSTEM; SEROLOGY; SOUTH AFRICA; VACCINATION;

ADULT; CARCINOMA, HEPATOCELLULAR; COINFECTION; DNA, VIRAL; FEMALE; HEPATITIS B E ANTIGENS; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HIV; HIV INFECTIONS; HUMANS; LIVER CIRRHOSIS; LIVER NEOPLASMS; MALE; PHYLOGENY; PREVALENCE; SOUTH AFRICA; VIRAL LOAD;

EID: 84891950003     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0074900     Document Type: Article

References (27)

1. Di Bisceglie AM, Maskew M, Schulze D, Reyneke A, McNamara L, et al. (2010) HIV-HBV coinfection among South African patients receiving antiretroviral therapy. Antiviral therapy 15: 499-503.
2. Hoffmann CJ, Charalambous S, Martin DJ, Innes C, Churchyard GJ, et al. (2008) Hepatitis B virus infection and response to antiretroviral therapy (ART) in a South African ART program. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 47: 1479-1485.
3. Law WP, Dore GJ, Duncombe CJ, Mahanontharit A, Boyd MA, et al. (2003) Risk of severe hepatotoxicity associated with antiretroviral therapy in the HIVNAT Cohort, Thailand, 1996-2001. Aids 17: 2191-2199. (Pubitemid 37338892)
4. Thio CL, Seaberg EC, Skolasky R Jr, Phair J, Visscher B, et al. (2002) HIV-1, hepatitis B virus, and risk of liver-related mortality in the Multicenter Cohort Study (MACS). Lancet 360: 1921-1926. (Pubitemid 35472132)
5. Alter H (2006) Viral hepatitis. Hepatology 43: S230-234.
6. Kramvis A, Kew MC (2007) Epidemiology of hepatitis B virus in Africa, its genotypes and clinical associations of genotypes. Hepatol Res 37: S9-S19. (Pubitemid 47086511)
7. Iloeje UH, Yang HI, Su J, Jen CL, You SL, et al. (2006) Predicting cirrhosis risk based on the level of circulating hepatitis B viral load. Gastroenterology 130: 678-686. (Pubitemid 43374518)
8. Chen CJ, Yang HI, Su J, Jen CL, You SL, et al. (2006) Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. Jama 295: 65-73. (Pubitemid 43042691)
9. Sterling RK, Lissen E, Clumeck N, Sola R, Correa MC, et al. (2006) Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection. Hepatology 43: 1317-1325. (Pubitemid 43980111)
10. Sanne I, Orrell C, Fox MP, Conradie F, Ive P, et al. (2010) Nurse versus doctor management of HIV-infected patients receiving antiretroviral therapy (CIPRASA): a randomised non-inferiority trial. Lancet 376: 33-40.
11. Mkumla NBD, Viana R, Ive P, McIntyre J, Wood R, et al. (2011) Drug Resistance patterns emerging in HIV/HBV-coinfected patients accessing a lamivudine-based regimen in South Africa. Antiviral Therapy 16: A28.
12. Tamura K, Peterson D, Peterson N, Stecher G, Nei M, et al. (2011) MEGA5: molecular evolutionary genetics analysis using maximum likelihood, evolutionary distance, and maximum parsimony methods. Mol Biol Evol 28: 2731-2739.
13. Alestig E, Soderstrom A, Norkrans G, Lindh M (2013) Genetic diversity of genotype D3 in acute hepatitis B. J Med Virol
14. Lo Re V 3rd, Frank I, Gross R, Dockter J, Linnen JM, et al. (2007) Prevalence, risk factors, and outcomes for occult hepatitis B virus infection among HIVinfected patients. J Acquir Immune Defic Syndr 44: 315-320. (Pubitemid 46328349)
15. Shire NJ, Rouster SD, Rajicic N, Sherman KE (2004) Occult Hepatitis B in HIV-Infected Patients. J Acquir Immune Defic Syndr 36: 869-875. (Pubitemid 38859354)
16. Wacholder S (1986) Binomial regression in GLIM: estimating risk ratios and risk differences. Am J Epidemiol 123: 174-184. (Pubitemid 16189710)
17. Soriano V, Puoti M, Peters M, Benhamou Y, Sulkowski M, et al. (2008) Care of HIV patients with chronic hepatitis B: updated recommendations from the HIVHepatitis B Virus International Panel. Aids 22: 1399-1410.
18. Colin JF, Cazals-Hatem D, Loriot MA, Martinot-Peignoux M, Pham BN, et al. (1999) Influence of human immunodeficiency virus infection on chronic hepatitis B in homosexual men. Hepatology 29: 1306-1310. (Pubitemid 29168769)
19. Tangkijvanich P, Sa-Nguanmoo P, Avihingsanon A, Ruxrungtham K, Poovorawan K, et al. (2013) Characterization of hepatitis B virus mutations in untreated patients co-infected with HIV and HBV based on complete genome sequencing. J Med Virol 85: 16-25.
20. Thio CL, Smeaton L, Saulynas M, Hwang H, Saravan S, et al. (2013) Characterization of HIV-HBV coinfection in a multinational HIV-infected cohort. Aids 27: 191-201.
21. Hoffmann CJ, Charalambous S, Martin DJ, Innes C, Churchyard GJ, et al. (2008) Hepatitis B virus infection and response to antiretroviral therapy (ART) in a South African ART program. Clin Infect Dis 47: 1479-1485.
22. Idoko J, Meloni S, Muazu M, Nimzing L, Badung B, et al. (2009) Impact of hepatitis B virus infection on human immunodeficiency virus response to antiretroviral therapy in Nigeria. Clin Infect Dis 49: 1268-1273.
23. Firnhaber C, Reyneke A, Schulze D, Malope B, Maskew M, et al. (2008) The prevalence of hepatitis B co-infection in a South African urban government HIV clinic. S Afr Med J 98: 541-544.
24. Vardas E, Mathai M, Blaauw D, McAnerney J, Coppin A, et al. (1999) Preimmunization epidemiology of hepatitis B virus infection in South African children. J Med Virol 58: 111-115. (Pubitemid 29226851)
25. Oshitani H, Kasolo FC, Mpabalwani M, Mizuta K, Luo NP, et al. (1996) Prevalence of hepatitis B antigens in human immunodeficiency virus type 1 seropositive and seronegative pregnant women in Zambia. Trans R Soc Trop Med Hyg 90: 235-236. (Pubitemid 26188858)
26. Tswana S, Chetsanga C, Nystrom L, Moyo S, Nzara M, et al. (1996) A seroepidemiological cross-sectional study of hepatitis B virus in Zimbabwe. S Afr Med J 86: 72-75. (Pubitemid 26058909)
27. World Health Organization (2010) Antiretroviral Therapy for HIV Infection in Adults and Adolescents: recommendations for a public health approach.-2010 rev. In: WHO, editor. Austria.